Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut
Sponsor: Guy Boeckxstaens
Summary
Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success. Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which probably contributes to the abdominal pain. A new product called "UCB8600" is hypothesized to be able to counteract this by causing less mast cells to be activated. In this study we'll test this by administering UCB8600 on intestinal tissue and see if there is less mast cell activation. If the study produces good results, this new product could potentially be used as a treatment for IBS in the future.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-06
Completion Date
2028-04
Last Updated
2026-06-17
Healthy Volunteers
Yes
Conditions
Interventions
Sample collection
Collection of colonic resection material (surgery patients) and rectal biopsies (IBS patients)
Locations (1)
University Hospitals Leuven
Leuven, Vlaams-Brabant, Belgium